Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772541 | 0.84 | BDKRB2 (0.54) | RORCBDKRB2 | |
| SCHEMBL4592164 | 0.84 | RORC (0.47) | RORCBDKRB2 | |
| SCHEMBL2638878 | 0.82 | RORC (0.56) | RORCBDKRB2 | |
| SCHEMBL6946090 | 0.79 | RORC (0.83) | RORCBDKRB2 | |
| SCHEMBL3743960 | 0.79 | RORC (0.83) | RORCBDKRB2 | |
| SCHEMBL1560107 | 0.79 | BDKRB2 (0.42) | RORCBDKRB2 | |
| SCHEMBL7814524 | 0.79 | BDKRB2 (0.47) | RORCBDKRB2 | |
| SCHEMBL8181772 | 0.74 | RORC (0.71) | RORCBDKRB2 | |
| SCHEMBL7952802 | 0.72 | RORC (0.72) | RORCBDKRB2 | |
| SCHEMBL6946877 | 0.71 | RORC (0.65) | RORCBDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303268-B1 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE | LUSO FARMACO INST (IT) | 2012-06-20 | — | — | EP | claimed |
| JP-2011527296-A | — | — | 2011-10-27 | — | — | JP | claimed |
| US-20100292156-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2010-11-18 | — | — | US | claimed |
| EP-2222275-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | Istituto Luso Farmaco d'Italia S.p.A. (IT) | 2010-09-01 | — | — | EP | claimed |
| WO-2010003601-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE | INSTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2010-01-14 | — | — | WO | claimed |
| WO-2009065507-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2009-05-28 | — | — | WO | claimed |
| US-9101627-B2 | Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2015-08-11 | — | — | US | disclosed |
| US-20100292156-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2010-11-18 | — | — | US | disclosed |
| EP-2222275-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | Istituto Luso Farmaco d'Italia S.p.A. (IT) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009065507-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292156-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | BDKRB2, BDKRB1, HCAR2 | RORC 3493/4885BDKRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.